ArticlePediatric radiology2013
Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.
Article in Pediatric radiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Dose-Lowering in Contrast-Enhanced MRI of the Central Nervous System: A Retrospective, Parallel-Group Comparison Using Gadobenate Dimeglumine.Journal of magnetic resonance imaging : JMRI · 2021Trial
- Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications.Investigative radiology · 2016Trial
- Optimizing neonatal cardiac imaging (magnetic resonance/computed tomography).Pediatric radiology · 2022Review
- PEGylation of Metal Oxide Nanoparticles Modulates Neutrophil Extracellular Trap Formation.Biosensors · 2022Article
- Liver magnetic resonance imaging: how we do it.Pediatric radiology · 2022Review
- Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants.AJNR. American journal of neuroradiology · 2019Article
- Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging.Indian journal of pediatrics · 2019Review
- Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Intravenous gadolinium-based hepatocyte-specific contrast agents (HSCAs) for contrast-enhanced liver magnetic resonance imaging in pediatric patients: what the radiologist should know.Pediatric radiology · 2019Review
- Practical administration of intravenous contrast media in children: screening, prophylaxis, administration and treatment of adverse reactions.Pediatric radiology · 2019Review
- Radiographic and magnetic resonances contrast agents: Essentials and tips for safe practices.World journal of radiology · 2017Review
- Pediatric Patients Demonstrate Progressive T1-Weighted Hyperintensity in the Dentate Nucleus following Multiple Doses of Gadolinium-Based Contrast Agent.AJNR. American journal of neuroradiology · 2016Article
- MRI of paediatric liver tumours: How we review and report.Cancer imaging : the official publication of the International Cancer Imaging Society · 2016Review
- Acute side effects of three commonly used gadolinium contrast agents in the paediatric population.The British journal of radiology · 2016Article
- Gadobenate-dimeglumine-enhanced magnetic resonance imaging for hepatic lesions in children.Pediatric radiology · 2014Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGadolinium-based MR contrast agents have long been considered safe for routine diagnostic imaging. However, the advent of nephrogenic systemic fibrosis (NSF) among certain patients with severe renal insufficiency has brought the issue of safety into question. Nowhere is safety of greater concern than among children who frequently require multiple contrast-enhanced MRI examinations over an extended period of time.
objectiveTo retrospectively evaluate the safety of gadobenate dimeglumine for contrast-enhanced (CE) MRI across a range of indications. MATERIALS AND
methodsTwo hundred pediatric inpatients (age: 4 days to 15 years) underwent CE MRI as part of clinical routine. The children received a gadobenate dimeglumine dose of either 0.05 mmol/kg body weight (liver, abdominal imaging, musculoskeletal imaging, brain and other rare indications) or 0.1 mmol/kg bodyweight (cardiovascular imaging, MR-urography). Young (< 8 years) children with congenital heart disease were intubated and underwent MRA evaluation with controlled ventilation. Monitoring for adverse events was performed for at least 24 h after each gadobenate dimeglumine injection. Depending on clinical necessity, laboratory measurements and, in some cases, vital sign and ECG determinations were made before and after contrast injection. Safety was evaluated by age group, indication and dose administered.
resultsNo clinically adverse events were reported among children who had one MRI scan only or among children who had several examinations. There were no changes in creatinine or bilirubin levels even in very young children.
conclusionsNo adverse events were recorded during the first 24 h following administration of gadobenate dimeglumine in 200 children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.